The world-wide shortage of all forms of Sinemet® has been ongoing for some time.
We can now confirm that Sinemet® will continue to be in short supply until possibly December 2019. The shortage is due to a problem at the manufacturer’s level.
Sinemet® 100/25 is completely out of stock however Kinson 100/25 (generic form of Sinemet®) remains available.
The pharmaceutical company which markets Sinemet® in Australia (Merck, Sharp & Dohme) is keeping prescribing doctors informed of the situation and is encouraging them to switch patients to the alternative brand of levodopa (Madopar®). NB This can only be done by a Dr.
An alternative to changing to Madopar® may be possible: an agreement with Therapeutic Goods Act (TGA) allows pharmacists to access an alternative brand of Sinemet® not previously available in Australia. The pharmacist should contact Medsurge Healthcare: email@example.com to investigate the availability of controlled release (CR) 200/50 and Immediate Release 250/25. NB This can only be done by a pharmacist.
Merck, Sharp & Dohme are keeping all Doctors, Pharmacists and Parkinson’s Australia informed of the situation.
We advise that if you are experiencing difficulties obtaining supplies of Sinemet® then contact your pharmacy with the above information or contact your prescribing doctor.
We will keep you updated as new information becomes available.